On Monday, Nektar Therapeutics (NASDAQ: NKTR) was 7.68% up from the session before settling in for the closing price of $8.59. A 52-week range for NKTR has been $6.48 – $22.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -3.00% over the last five years. When this article was written, the company’s average yearly earnings per share was at -40.83%. With a float of $11.96 million, this company’s outstanding shares have now reached $12.41 million.
The firm has a total of 61 workers. Let’s measure their productivity. In terms of profitability, gross margin is 74.61%, operating margin of -131.01%, and the pretax margin is -147.55%.
Nektar Therapeutics (NKTR) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Nektar Therapeutics stocks. The most recent insider transaction that took place on May 19 ’25, was worth 7,177. In this transaction Chief R&D Officer of this company sold 10,712 shares at a rate of $0.67, taking the stock ownership to the 305,892 shares. Before that another transaction happened on May 19 ’25, when Company’s Chief Legal Officer sold 9,996 for $0.67, making the entire transaction worth $6,697. This insider now owns 314,296 shares in total.
Nektar Therapeutics (NKTR) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -40.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -16.69% during the next five years compared to 25.49% growth over the previous five years of trading.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
You can see what Nektar Therapeutics (NKTR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -9.53, a number that is poised to hit -2.98 in the next quarter and is forecasted to reach -12.07 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Analysing the last 5-days average volume posted by the [Nektar Therapeutics, NKTR], we can find that recorded value of 0.74 million was better than the volume posted last year of 0.18 million. As of the previous 9 days, the stock’s Stochastic %D was 19.06%. Additionally, its Average True Range was 1.31.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 28.72%, which indicates a significant increase from 28.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 165.40% in the past 14 days, which was higher than the 110.09% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.95, while its 200-day Moving Average is $14.32. Now, the first resistance to watch is $9.90. This is followed by the second major resistance level at $10.54. The third major resistance level sits at $11.50. If the price goes on to break the first support level at $8.30, it is likely to go to the next support level at $7.34. Should the price break the second support level, the third support level stands at $6.70.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
There are 12,413K outstanding shares of the company, which has a market capitalization of 114.76 million. As of now, sales total 98,430 K while income totals -118,960 K. Its latest quarter income was 10,460 K while its last quarter net income were -50,880 K.
